Treace Medical Concepts, Inc. Selling and Marketing Expense
Treace Medical Concepts, Inc. (TMCI) reported Selling and Marketing Expense of $30.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-07
- Treace Medical Concepts, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $30.94M, a 6.48% decline year-over-year.
- Treace Medical Concepts, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $33.77M, a 6.50% decline year-over-year.
- Treace Medical Concepts, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $37.25M, a 1.07% increase year-over-year.
- Treace Medical Concepts, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $34.42M, a 5.02% increase year-over-year.
- Treace Medical Concepts, Inc. selling and marketing expense for fiscal 2025 was $140.88M, a 4.58% decline from fiscal 2024.
- Treace Medical Concepts, Inc. selling and marketing expense for fiscal 2024 was $147.64M, a 4.79% increase from fiscal 2023.
- Treace Medical Concepts, Inc. selling and marketing expense for fiscal 2023 was $140.89M, a 34.74% increase from fiscal 2022.
- Treace Medical Concepts, Inc. selling and marketing expense for fiscal 2022 was $104.57M, a 59.88% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.94M 10-Q · filed 2026-08-07 | $64.72M 10-Q · filed 2026-08-07 | $101.97M derived: sum of 3 quarters · filed 2026-08-07 | $136.39M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $33.77M 10-Q · filed 2026-05-08 | $71.03M derived: sum of 2 quarters · filed 2026-05-08 | $105.45M derived: sum of 3 quarters · filed 2026-05-08 | $138.53M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $37.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $71.67M derived: sum of 2 quarters · filed 2026-02-27 | $104.76M derived: sum of 3 quarters · filed 2026-08-07 | $140.88M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $34.42M 10-Q · filed 2025-11-06 | $67.50M derived: sum of 2 quarters · filed 2026-08-07 | $103.63M 10-Q · filed 2025-11-06 | $140.49M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $33.08M 10-Q · filed 2026-08-07 | $69.21M 10-Q · filed 2026-08-07 | $106.06M derived: sum of 3 quarters · filed 2026-08-07 | $138.84M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $36.12M 10-Q · filed 2026-05-08 | $72.98M derived: sum of 2 quarters · filed 2026-05-08 | $105.76M derived: sum of 3 quarters · filed 2026-05-08 | $143.44M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $36.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $69.63M derived: sum of 2 quarters · filed 2026-02-27 | $107.31M derived: sum of 3 quarters · filed 2026-02-27 | $147.64M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $32.77M 10-Q · filed 2025-11-06 | $70.46M derived: sum of 2 quarters · filed 2025-11-06 | $110.78M 10-Q · filed 2025-11-06 | $150.71M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $37.68M 10-Q · filed 2025-08-07 | $78.01M 10-Q · filed 2025-08-07 | $117.93M derived: sum of 3 quarters · filed 2026-02-27 | $151.47M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $40.33M 10-Q · filed 2025-05-08 | $80.25M derived: sum of 2 quarters · filed 2026-02-27 | $113.79M derived: sum of 3 quarters · filed 2026-02-27 | $147.57M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $39.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $73.47M derived: sum of 2 quarters · filed 2026-02-27 | $107.24M derived: sum of 3 quarters · filed 2026-02-27 | $140.89M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $33.54M 10-Q · filed 2024-11-05 | $67.31M derived: sum of 2 quarters · filed 2024-11-05 | $100.97M 10-Q · filed 2024-11-05 | $131.06M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $33.77M 10-Q · filed 2024-08-06 | $67.43M 10-Q · filed 2024-08-06 | $97.52M derived: sum of 3 quarters · filed 2025-02-27 | $123.09M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $33.66M 10-Q · filed 2024-05-07 | $63.74M derived: sum of 2 quarters · filed 2025-02-27 | $89.31M derived: sum of 3 quarters · filed 2025-02-27 | $115.92M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $30.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $55.66M derived: sum of 2 quarters · filed 2025-02-27 | $82.27M derived: sum of 3 quarters · filed 2025-02-27 | $104.57M 10-K · filed 2025-02-27 | $102.58M 10-K · filed 2023-03-08 | |||
| 2022-09-30 | $25.57M 10-Q · filed 2023-11-09 | $25.03M 10-Q · filed 2022-11-09 | $52.18M derived: sum of 2 quarters · filed 2023-11-09 | $74.48M 10-Q · filed 2023-11-09 | $73.21M 10-Q · filed 2022-11-09 | $97.74M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $26.61M 10-Q · filed 2023-08-09 | $26.25M 10-Q · filed 2022-08-10 | $48.91M 10-Q · filed 2023-08-09 | $48.17M 10-Q · filed 2022-08-10 | $72.17M derived: sum of 3 quarters · filed 2024-02-27 | $88.16M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $22.30M 10-Q · filed 2023-05-09 | $21.92M 10-Q · filed 2022-05-06 | $45.56M derived: sum of 2 quarters · filed 2024-02-27 | $61.55M derived: sum of 3 quarters · filed 2024-02-27 | $75.56M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $23.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $39.25M derived: sum of 2 quarters · filed 2024-02-27 | $53.26M derived: sum of 3 quarters · filed 2024-02-27 | $65.41M 10-K · filed 2024-02-27 | $64.47M 10-K · filed 2022-03-04 | |||
| 2021-09-30 | $15.98M 10-Q · filed 2022-11-09 | $29.99M derived: sum of 2 quarters · filed 2022-11-09 | $42.14M 10-Q · filed 2022-11-09 | $53.57M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-06-30 | $14.01M 10-Q · filed 2022-08-10 | $26.16M 10-Q · filed 2022-08-10 | $37.58M derived: sum of 3 quarters · filed 2023-03-08 | $45.69M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2021-03-31 | $12.15M 10-Q · filed 2022-05-06 | $23.57M derived: sum of 2 quarters · filed 2023-03-08 | $31.68M derived: sum of 3 quarters · filed 2023-03-08 | $36.47M derived: sum of 4 quarters · filed 2023-03-08 | ||||
| 2020-12-31 | $11.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $19.53M derived: sum of 2 quarters · filed 2023-03-08 | $24.32M derived: sum of 3 quarters · filed 2023-03-08 | $31.65M 10-K · filed 2023-03-08 | ||||
| 2020-09-30 | $8.10M 10-Q · filed 2021-11-04 | $12.89M derived: sum of 2 quarters · filed 2021-11-04 | $20.23M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $4.79M 10-Q · filed 2021-08-05 | $12.13M 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $7.34M 10-Q · filed 2021-05-25 | |||||||
| 2019-12-31 | $25.79M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |